KRMD trades 52.2% below Wall Street's consensus target of $7.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes KRMD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, KORU Medical Systems, Inc. (KRMD) has a Wall Street consensus price target of $7.00, based on estimates from 5 covering analysts. With the stock currently trading at $4.60, this represents a potential upside of +52.2%. The company has a market capitalization of $211M.
Analyst price targets range from a low of $7.00 to a high of $7.00, representing a 0% spread in expectations. The median target of $7.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, KRMD trades at a trailing P/E of -80.6x. Analysts expect EPS to grow +10.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ATRCAtriCure, Inc. | $1.6B | $32.39 | $51.33 | +58.5% | Buy | 915.0x | 19 |
INFUInfuSystem Holdings, Inc. | $201M | $9.97 | $15.00 | +50.5% | Buy | 23.5x | 3 |
LMATLeMaitre Vascular, Inc. | $2.4B | $103.72 | $127.50 | +22.9% | Buy | 34.6x | 20 |
BDXBecton, Dickinson and Company | $56.4B | $155.54 | $174.81 | +12.4% | Hold | 12.4x | 34 |
BAXBaxter International Inc. | $11.7B | $22.58 | $20.71 | -8.3% | Hold | 11.8x | 36 |
ICUSeaStar Medical Holding Corporation | $187M | $4.76 | $8.00 | +68.1% | Buy | — | 1 |
AVNSAvanos Medical, Inc. | $1.2B | $24.92 | $23.00 | -7.7% | Hold | 24.9x | 8 |
MMSIMerit Medical Systems, Inc. | $4.3B | $71.45 | $94.20 | +31.8% | Buy | 17.6x | 14 |
NXRTNexPoint Residential Trust, Inc. | $723M | $28.47 | $26.00 | -8.7% | Hold | — | 10 |
TNDMTandem Diabetes Care, Inc. | $1.1B | $15.42 | $29.95 | +94.2% | Buy | — | 39 |
Quick answers to the most common questions about buying KRMD stock.
The consensus Wall Street price target for KRMD is $7, representing 52.2% upside from the current price of $4.6. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
KRMD has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $7 implies 52.2% upside from current levels.
KRMD's current price is $4.6 with a consensus target of $7 (52.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $7 for KRMD, while the most conservative target is $7. The consensus of $7 represents the median expectation. These targets typically reflect 12-month expectations.
KRMD is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month KRMD stock forecast based on 5 Wall Street analysts shows a consensus price target of $7, with estimates ranging from $7 (bear case) to $7 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on KRMD, with a "Buy" consensus rating and $7 price target (52.2% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
KRMD analyst price targets range from $7 to $7, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.